Devonian Health Group Inc
XTSX:GSD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Devonian Health Group Inc
Pre-Tax Income
Devonian Health Group Inc
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Devonian Health Group Inc
XTSX:GSD
|
Pre-Tax Income
-CA$6.5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Pre-Tax Income
$367m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Pre-Tax Income
-CA$326.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Pre-Tax Income
-$17.1m
|
CAGR 3-Years
48%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Pre-Tax Income
-$168.1m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
-112%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Pre-Tax Income
-CA$6.7m
|
CAGR 3-Years
47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Devonian Health Group Inc
Glance View
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Pointe-Claire, Quebec. The company went IPO on 2014-09-09. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies, as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a Phase II clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The firm is also involved in the development of cosmeceutical products.
See Also
What is Devonian Health Group Inc's Pre-Tax Income?
Pre-Tax Income
-6.5m
CAD
Based on the financial report for Oct 31, 2025, Devonian Health Group Inc's Pre-Tax Income amounts to -6.5m CAD.
What is Devonian Health Group Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
3%
Over the last year, the Pre-Tax Income growth was -656%. The average annual Pre-Tax Income growth rates for Devonian Health Group Inc have been -20% over the past three years , 3% over the past five years .
